Elaine V. Jones, Ph.D. joined Pfizer Venture Investments as Executive Director, Venture Capital in 2008.  She is responsible for making and managing venture investments for Pfizer and currently oversees the PVI investments in Autifony Therapeutics Ltd. (London, UK),  CytomX Therapeutics (NASDAQ: CTMX),  Mersana Therapeutics (Cambridge, MA),  Merus B.V. (Utrecht, The Netherlands),  MIRNA Therapeutics (Austin, TX),  MISSION Therapeutics (Cambridge, UK),  Nimbus Therapeutics LLC. (Cambridge, MA),  Quartet Medicine (Cambridge, MA) and Ziarco Pharma (Canterbury, UK).  Elaine brings 16 years of venture capital experience and a strong background in research and product assessment, built on her significant experience in pharmaceutical drug discovery and business development to the PVI team.  

Most recently, Elaine was a General Partner with the venture fund, EuclidSR Partners.  There, she was responsible for the fund’s investments in Acurian, Fluidigm, InnaPhase and Targacept.  

Prior to joining ESR, Dr. Jones began her private equity career in 1999 at S.R. One, GlaxoSmithKline’s venture fund, where she managed investments including Adolor, Avantium, Nucleonics, Scynexis and Vicuron.  Previously, she served as Director of Scientific Licensing for SmithKline Beecham and was a research scientist in SmithKline Beecham Pharmaceutical R&D.  

Dr. Jones is a graduate of Juniata College and received her Ph.D. in Microbiology from the University of Pittsburgh.